Evidence map›Paper›PMID 37799065›Full record

ArticleHuman vaccines & immunotherapeutics2023

Hospitalization burden related to herpes zoster infection during the COVID-19 pandemic in Spain (2020-2021).

Victor-Manuel Irigoyen-Mansilla, Ruth Gil-Prieto, Enrique Gea-Izquierdo, José Luis Barrio-Fernández, Valentín Hernández-Barrera, Angel Gil-de-Miguel

Open access · goldAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Victor-Manuel Irigoyen-MansillaPreventive Medicine Unit, Infanta Sofia University Hospital, San Sebastián de los Reyes, Spain.
Ruth Gil-PrietoDepartment of Medical Specialities and Public Health. Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Madrid, Spain.ORCID 0000-0002-5229-3832
Enrique Gea-IzquierdoDepartment of Medical Specialities and Public Health. Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Madrid, Spain.
José Luis Barrio-FernándezDepartment of Medical Specialities and Public Health. Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Madrid, Spain.
Valentín Hernández-BarreraDepartment of Medical Specialities and Public Health. Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Madrid, Spain.
Angel Gil-de-MiguelDepartment of Medical Specialities and Public Health. Area of Preventive Medicine & Public Health, Rey Juan Carlos University, Madrid, Spain.
Universidad Rey Juan Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Varicella-Zoster Virus (VZV) belongs to the family Herpesviridae. Herpes zoster (HZ) is caused by reactivation of latent VZV. It is associated with risk factors such as immunosenescence, immunosuppressive pathologies and pharmacological treatments. Patients with these risk factors are more likely to be hospitalized. Increases in HZ hospitalizations have been reported in many countries in recent years. The objective of this study is to estimate hospitalization rates, mortality rates and costs due to HZ during the worst years of the COVID-19 pandemic in Spain (2020-2021). This is a descriptive study based on an analysis of information from the Minimum Basic Dataset and coded according to the Spanish version of the 10th International Classification of Diseases (ICD-10-CM). Hospitalization, mortality and case-fatality rates, and median length of hospitalization were calculated.. The hospitalization rate was 14.4 cases per 100,000 inhabitants, and the mortality rate was 1.3 cases per 100,000 inhabitants. Both increased considerably with age. In this time period, 92.3% of the registered cases were people over 50 years of age. Nevertheless, during the COVID-19 pandemic period, hospitalization rate decreased and the mortality rate increased from previous years. HZ hospitalization and mortality rates are relevant issues in the public health of older people. It is highly recommended to evaluate new vaccination strategies against VZV to include the HZ vaccine for health care for elderly people, as well as to reduce the disease burden and associated risk factors. The estimation of HZ disease hospitalization costs were €100,433,904.

Indexed as

COVID-19Herpes ZosterHerpes Zoster VaccineAgedHerpesvirus 3, HumanHospitalizationHumansIncidenceMiddle AgedPandemicsSpainHerpes Zoster VaccineCOVID-19epidemiologyHerpes zosterhospitalizationsmortalitySARS-CoV-2Spainvaccinationvaricella-zoster virus

Identifiers

PMID37799065
PMCPMC10561580
OpenAlexW4387392027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.